MESA heart disease risk score performs well even without race modifiers

A version of the MESA heart disease risk score that did not include race predicted heart disease risk just as well as the version that includes race, according to a preliminary study presented today at the American Heart Association’s Scientific Sessions 2024.

Mount Sinai mounted aggressive campaign to stifle debate over revelations about its controversial brain research

Audrey Carleton, Bruce Gil, Emily Nadal, and Zachary Smith contributed reporting. Support for this project was provided by the Fund for Investigative Journalism. Mount Sinai,

July 31, 2024

Strategic partnership to revolutionize urine testing

Alpha Laboratories Ltd. (Hampshire, UK) is proud to announce that it has entered into a strategic partnership with Clinical Design Technologies Ltd. (Devon, UK), to

August 28, 2024

MacroGenics investigates three patient deaths in Phase 2 prostate cancer drug trial

MacroGenics reported on Thursday afternoon that three patients died in a mid-stage trial of its antibody-drug conjugate for prostate cancer. Two participants died due to

May 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.